Home ivps4 2017-06-16T21:39:52+00:00

News Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Investor Alerts

Sep 18, 2020

Achieve Announces Presentation of Investigator-Led RAUORA Trial Data Demonstrating Significantly Fewer Side Effects with Higher Quit Rates for Cytisinicline (cytisine) Compared to Chantix® (varenicline) in First Head-to-Head Comparative Study

Subjects in the Cytisinicline Arm Were 55% More Likely to Quit Smoking at 6 Months Compared to Subjects Who Received Varenicline
Sep 18, 2020

Achieve Life Sciences Announces Results from Evaluation of Cytisinicline (cytisine) versus Chantix® (varenicline) in 5-HT3 Receptor Binding Assay Study

Provides Mechanistic Rationale for the Clinical Findings that Cytisinicline (Cytisine) Treatment is Associated with Lower Rates of Nausea and Vomiting compared to Chantix
Sep 10, 2020

Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 20th Annual Society for Research on Nicotine & Tobacco Europe (SRNT-E) Virtual Conference
Sep 3, 2020

Achieve Life Sciences to Present at Upcoming Investor Conferences
Aug 6, 2020

Achieve Reports Financial Results for Second Quarter 2020 and Provides Update on Cytisinicline Development Program
Aug 4, 2020

Achieve Life Sciences Announces Pricing of $6.5 Million Public Offering
Aug 3, 2020

Achieve Life Sciences Announces Proposed Public Offering
Jul 31, 2020

Achieve Announces Patent Granted in the U.S. for Novel Analogs of Cytisinicline for Use in CNS and Addiction Indications
Jul 28, 2020

Achieve Life Sciences to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020
Jun 29, 2020

Achieve Life Sciences Announces Pricing of $6 Million Registered Direct Offering
Jun 29, 2020

Achieve Announces Successful Results from the Investigator-Initiated RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix® (varenicline) as a Treatment to Quit Smoking
May 14, 2020

Achieve Reports Financial Results for First Quarter 2020 and Provides Update on Cytisinicline Development Program
May 5, 2020

Achieve Life Sciences to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 14, 2020
Apr 30, 2020

Achieve Life Sciences Announces Private Placement of $1.9 Million
Mar 13, 2020

Achieve Reports Financial Results for Fourth Quarter and Year-End 2019 and Provides Update on Cytisinicline Development Program
Mar 12, 2020

Achieve Life Sciences Announces Presentation of Additional Cytisinicline Analyses at the Society for Research on Nicotine & Tobacco (SRNT) Annual Meeting
Mar 3, 2020

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2019 Financial Results and Host Conference Call and Webcast on March 13, 2020
Feb 6, 2020

Achieve Life Sciences Announces Agreement with the FreeMind Group to Assist in Securing Non-Dilutive Funding to Evaluate Cytisinicline in Vaping and e-Cigarette Users
Jan 13, 2020

Achieve Life Sciences, University of Bristol, and Oracle Corporation Announce Study Results Demonstrating Potential for Accelerated Speed of Drug Discovery
Dec 19, 2019

Achieve Life Sciences, Inc. Announces Closing of $13.8 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
Dec 17, 2019

Achieve Life Sciences Announces Pricing of $12 Million Underwritten Public Offering
Dec 9, 2019

Achieve Life Sciences Announces Completion of Meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline Smoking Cessation Phase 3 Clinical Development Program
Nov 6, 2019

Achieve Reports Financial Results for Third Quarter 2019 and Provides Update on Cytisinicline Development Program
Oct 31, 2019

Achieve Life Sciences to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 6, 2019
Oct 24, 2019

Achieve Life Sciences Announces Presentation of Cytisinicline Data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference
Sep 30, 2019

Achieve Life Sciences Announces Completion of Maximum Tolerated Dose Study
Sep 13, 2019

Achieve Life Sciences Announces Final Phase 2b ORCA-1 Trial Data Presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
Sep 5, 2019

Achieve Life Sciences to Host Investor Day on September 20th Including Roundtable Discussion with Smoking Cessation Medical Experts and Final Data from the Phase 2b ORCA-1 Trial
Sep 4, 2019

Achieve Life Sciences Announces Presentations at Upcoming Investor Conferences
Aug 8, 2019

/C O R R E C T I O N -- Achieve Life Sciences, Inc./
Jul 30, 2019

Achieve Life Sciences to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
Jul 23, 2019

Achieve Life Sciences Extends Collaboration with the National Institutes of Health to Advance the Development of Cytisinicline for Smoking Cessation
Jun 21, 2019

Achieve Life Sciences Announces Phase 2b ORCA-1 Trial Data Accepted for Oral Presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
Jun 11, 2019

Achieve Life Sciences Announces Statistically Significant Improvement in Quit Rates for Simplified Cytisinicline Dosing Schedule in Phase 2b ORCA-1 Dose-Selection Trial
Jun 3, 2019

Achieve Receives $4.2 Million from Exercise of Warrants
May 30, 2019

Achieve Announces Patent Granted in the U.S. for Novel Formulation of Cytisinicline
May 15, 2019

Achieve Reports Financial Results for First Quarter 2019 and Provides Cytisinicline Clinical Development Update
May 7, 2019

Achieve Life Sciences to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 15, 2019
Apr 24, 2019

Achieve Life Sciences Announces Last Subject, Last Visit Completed in Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation

Topline data from ORCA-1 trial expected in the Second Quarter of 2019
Apr 3, 2019

Achieve Life Sciences to Present at HC Wainwright Global Life Sciences Conference on April 8, 2019
Apr 2, 2019

Achieve Life Sciences Announces Successful Completion of the Second and Final DSMC Review of Phase 2b ORCA-1 Trial of Cytisinicline for Smoking Cessation

Topline data from ORCA-1 trial expected in the Second Quarter of 2019
Mar 18, 2019

Achieve Life Sciences to Present at Oppenheimer's 29th Annual Healthcare Conference on March 20, 2019
Mar 14, 2019

Achieve Reports Financial Results for Year-End 2018 and Provides Cytisinicline Clinical Development Update
Mar 5, 2019

Achieve Life Sciences to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call and Webcast on March 14, 2019
Feb 22, 2019

Achieve Announces Final Data from Cytisinicline Phase I/II Multi-Dose, Pharmacokinetic and Pharmacodynamics (PK/PD) Clinical Study to be Presented at Society for Research on Nicotine & Tobacco Annual Meeting
Feb 20, 2019

Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation

Topline data from ORCA-1 trial expected in mid-2019
Dec 18, 2018

Achieve Announces Update on Cytisinicline Clinical Development Program
Nov 7, 2018

Achieve Reports Financial Results for Third Quarter 2018 and Provides Cytisinicline (Cytisine) Clinical Development Update
Oct 31, 2018

Achieve Life Sciences to Announce Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 7, 2018
Oct 30, 2018

Achieve Life Sciences Announces Initiation of Phase 2b ORCA-1 Trial Evaluating Cytisinicline (cytisine) for Smoking Cessation

Show per page

Stock Info